As per the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure, as a platform approach for the purification of albumin and albumin-fusion proteins.
Reportedly, ProMetic will be the exclusive manufacturer and supplier of AlbuPure, however both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure.
ProMetic and Novozymes Biopharma, a subsidiary of Novozymes, have collaborated on the development of AlbuPure which was derived from ProMetic’s Mimetic Ligand technology and targeted at the capture and purification of recombinant albumin proteins produced in yeast. AlbuPure binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse albumin-fusion protein.
Dave Mead, business development director at Novozymes Biopharma, said: “This alliance with ProMetic will enable us to expand the technology package offered to our clients to include both protein expression and protein purification technology for albumin-fusion proteins.
“The availability of a robust affinity capture step, fully supported by Novozymes Biopharma and ProMetic, will provide advantages to our clients, including reduced development times and simplified high-yield manufacturing processes. The AlbuPure development builds on a good and long-standing relationship between our two companies.”